Author name: Nadia Farouk

TUDCA reduced artery narrowing after injury, plaque and aneurysm size in rats, rabbits and mice. No human artery trial exists. What each study tested.

TUDCA protected cartilage and spinal disc cells from ER stress in lab studies, but one study found no effect on cell death. No human joint trial exists.

TUDCA reduced seizure severity in two rat models at 500 mg/kg injected. There are no human trials, and epilepsy drugs must not be self-adjusted.

Five studies find TUDCA protects hair cells from cisplatin, gentamicin and a genetic deafness mutation. All are in rodents, at doses no capsule delivers.

Progressive MS is one of the very few conditions where TUDCA has been through a double-blind, placebo-controlled human trial. Here is what that trial was designed to answer, what it found, and the large question it deliberately left open.

Twenty days of TUDCA increased muscle mass and restored fibre size in 18-month-old mice. Combined with the human insulin-sensitivity trial, it is the most interesting muscle evidence TUDCA has. Here is how far it goes.

A small open-label trial gave patients with active ulcerative colitis oral TUDCA for six weeks and measured endoscopic and histologic change. What it found, and the four reasons the result needs a controlled trial before it means much.

TUDCA and kidney function: what the animal research on acute kidney injury, diabetic nephropathy, and ER stress shows, and why human trials don’t exist yet.